JoAnne Foody1, Robin S Turpin2, Beni A Tidwell3, Debra Lawrence4, Kathy L Schulman5. 1. Associate Professor, Harvard Medical School, Boston, MA, and Executive Director-Cardiovascular, Janssen Pharmaceuticals, New Brunswick, NJ. 2. Director and Head, Health Economics and Outcomes Research, Medical Affairs, Takeda Pharmaceuticals USA, Deerfield, IL. 3. Research Associate, Outcomes Research Solutions, Shrewsbury, MA. 4. Director, Health Economics and Outcomes Research; Medical Affairs, Takeda Pharmaceuticals USA. 5. Research Scientist and Principal, Outcomes Research Solutions, Shrewsbury, MA.
Abstract
BACKGROUND: Several observational studies and meta-analyses have suggested that treating hyperuricemia in patients with gout and moderate or severe chronic kidney disease (CKD) may improve renal and cardiovascular (CV) outcomes. OBJECTIVE: To evaluate the impact of initiating allopurinol or febuxostat treatment on major CV events in patients with gout, preexisting CV disease (CVD) or heart failure (HF), and stage 3 or 4 CKD in a real-world setting. METHODS: Patients with gout (aged >18 years) who initiated allopurinol or febuxostat treatment between 2009 and 2013 after a diagnosis of stage 3 or 4 CKD and CVD-including coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (PVD)-or HF were selected from the MarketScan databases. The major CV events included CAD-specific, cerebrovascular disease-specific, and PVD-specific events. Cox proportional hazards modeling identified the predictors of major CV events in aggregate, and of CAD, cerebrovascular disease, and PVD events, individually. RESULTS: During follow-up, 2426 patients (370 receiving febuxostat and 2056 receiving allopurinol; 63% male; mean age, 73 years) had 162 major CV events (3.8% in those receiving febuxostat vs 7.2% in those receiving allopurinol; P = .015). The rates of major CV events per 1000 person-years were 51.8 (95% confidence interval [CI], 28-87) in patients initiating febuxostat and 99.3 (95% CI, 84-117) among those initiating allopurinol. Overall, 49.4% of patients had a CAD event, 32.5% had a PVD event, and 23.5% had a cerebrovascular disease-specific event. Febuxostat initiation was associated with a significantly lower risk for a major CV event versus patients who initiated allopurinol (hazard ratio, 0.52; P = .02), driven in large part by lower PVD-specific events (P = .026). CONCLUSION: Patients with moderate-to-severe CKD and CVD or HF who initiated febuxostat treatment had a significantly lower rate of major CV events than patients who initiated allopurinol.
BACKGROUND: Several observational studies and meta-analyses have suggested that treating hyperuricemia in patients with gout and moderate or severe chronic kidney disease (CKD) may improve renal and cardiovascular (CV) outcomes. OBJECTIVE: To evaluate the impact of initiating allopurinol or febuxostat treatment on major CV events in patients with gout, preexisting CV disease (CVD) or heart failure (HF), and stage 3 or 4 CKD in a real-world setting. METHODS: Patients with gout (aged >18 years) who initiated allopurinol or febuxostat treatment between 2009 and 2013 after a diagnosis of stage 3 or 4 CKD and CVD-including coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (PVD)-or HF were selected from the MarketScan databases. The major CV events included CAD-specific, cerebrovascular disease-specific, and PVD-specific events. Cox proportional hazards modeling identified the predictors of major CV events in aggregate, and of CAD, cerebrovascular disease, and PVD events, individually. RESULTS: During follow-up, 2426 patients (370 receiving febuxostat and 2056 receiving allopurinol; 63% male; mean age, 73 years) had 162 major CV events (3.8% in those receiving febuxostat vs 7.2% in those receiving allopurinol; P = .015). The rates of major CV events per 1000 person-years were 51.8 (95% confidence interval [CI], 28-87) in patients initiating febuxostat and 99.3 (95% CI, 84-117) among those initiating allopurinol. Overall, 49.4% of patients had a CAD event, 32.5% had a PVD event, and 23.5% had a cerebrovascular disease-specific event. Febuxostat initiation was associated with a significantly lower risk for a major CV event versus patients who initiated allopurinol (hazard ratio, 0.52; P = .02), driven in large part by lower PVD-specific events (P = .026). CONCLUSION: Patients with moderate-to-severe CKD and CVD or HF who initiated febuxostat treatment had a significantly lower rate of major CV events than patients who initiated allopurinol.
Authors: Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon Journal: Am J Med Date: 2015-02-03 Impact factor: 4.965
Authors: Chaitanya A Sarawate; Pankaj A Patel; H Ralph Schumacher; Wenya Yang; Kathleen K Brewer; Alan W Bakst Journal: J Clin Rheumatol Date: 2006-04 Impact factor: 3.517
Authors: Davide Grassi; Giovambattista Desideri; Anna Vittoria Di Giacomantonio; Paolo Di Giosia; Claudio Ferri Journal: High Blood Press Cardiovasc Prev Date: 2014-02-20
Authors: Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher Journal: Arthritis Res Ther Date: 2010-04-06 Impact factor: 5.156
Authors: Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe Journal: Arthritis Rheum Date: 2008-01
Authors: Mehmet Kanbay; Mark Segal; Baris Afsar; Duk-Hee Kang; Bernardo Rodriguez-Iturbe; Richard J Johnson Journal: Heart Date: 2013-01-23 Impact factor: 5.994
Authors: Seoyoung C Kim; Bernhard M W Schmidt; Jessica M Franklin; Jun Liu; Daniel H Solomon; Sebastian Schneeweiss Journal: Arthritis Care Res (Hoboken) Date: 2013-12 Impact factor: 4.794